bd-capital, the pan-European private equity firm, completed the investment in Symprove, a probiotics company. Financial terms were not disclosed. "We were aware that we needed serious help to take Symprove to the next level and it was clear to us that bd-capital could bring a huge level of expertise and experience to the task. More importantly, however, what sets bd-capital apart is their care and consideration; they are eager to safeguard Symprove’s heritage and brand integrity as the company enters its next chapter of growth. bd-capital’s excitement to work with us is palpable and the entire Symprove team feel the same way; I am in no doubt that we have selected an exceptional partner," Barry Smith, Symprove Founder.